Atogepant (MK-8031) is an orally available, selective and potent calcitonin gene-related peptide receptor (CGRP) antagonist for the study of migraine.

CGRP receptors (rhesus macaque):0.009 nM (Ki), CGRP receptors (rat):0.7 nM (Ki), CGRP receptors (rabbit):2.1 nM (Ki), CGRP receptors (human natural):0.026 nM (Ki), CGRP (human cloned):0.026 nM, CGRP receptors (human cloned):0.015 nM (Ki), CGRP receptors (dog):1.2 nM (Ki), CGRP receptors (mouse):0.13 nM (Ki)

Atogepant has a CGRP IC50=0.026 nM for human clones.
The binding affinities of Atogepant for human and non-human CGRP receptors were: human (cloned) Ki=0.015 nM, human (natural) Ki=0.026 nM, rhesus macaque Ki=0.009 nM, rat Ki=0.7 nM, mouse Ki=0.13 nM, rabbit Ki=2.1 nM, dog Ki=1.2 nM, respectively. [1][2]

Oral administration of Atogepant to rats (at doses of 3, 10, and 30 mg/kg, respectively) once daily for 9 days showed that Atogepant effectively attenuated the abnormal facial pain induced by nitroglycerin and ameliorated the capsaicin-induced vasodilation of primate dermis in rats.[2]